QUVIVIQ

Peak

daridorexant

NDAORALTABLET
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1

Mechanism of Action

Orexin Receptor Antagonists

Pharmacologic Class:

Orexin Receptor Antagonist

Clinical Trials (1)

NCT07028697Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

Started Dec 2024

Loss of Exclusivity

LOE Date
Dec 2, 2034
106 months away
Patent Expiry
Dec 2, 2034
Exclusivity Expiry
Sep 30, 2027

Patent Records (3)

Patent #ExpiryTypeUse Code
9732075
Jun 12, 2033
SubstanceProduct
U-620
10023560
Dec 2, 2034
U-620
9790208
Dec 2, 2034
SubstanceProduct